Medtronic recently announced the three-month results from a large, multicenter randomized controlled trial (RT) showing statistically significant and superior back pain relief through Differential Target Multiplexed (DTM™) Spinal Cord Stimulation (SCS) compared to conventional SCS. Both therapies were evaluated using the Intellis™ neurostimulator. The trials began on the hypothesis of: Do glial and neuronal cells
BioSerenity, Inc., recently announced they received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Neuronaute® Electroencephalography (EEG) System and IceCap® EEG wearable device that allows physicians to remotely monitor patients with epilepsy. In general, EEG devices record the electrical activity of neurons in the brain through electrodes placed on the scalp (non-invasive) or
The novel coronavirus (COVID-19; SARS-CoV-2) pandemic has affected millions worldwide. There are still many unknowns surrounding this virus yet one thing is for sure, in serious cases the virus causes devastating effect on the body – and not just on the lungs. “Neurology Online Journal“ has published a new study showing that the COVID-19 virus
NeuroPace RNS System for Epilepsy Received FDA Approval for MRI LabelingNeuroPace announced that its RNS® System has received FDA approval for MRI labeling, increasing number treatment options for approximately one million patients living with drug resistant focal epilepsy. Similar to a pacemaker that responds to abnormal heart rhythms, the RNS® System is programmed to detect
Abbott‘s Low-Dose Neuromodulation Implant for Chronic Pain, Proclaim XR, was recently featured at 2020 International CES. Proclaim XR can connect to Apple products via Bluetooth and to enables patients to have more control over their treatment to regulate their pain as needed. Treatment plans can be updated and modified as new therapies are approved and
Register to receive a free Global Neurological Devices Market Analysis, Size, and Trends Report synopsis and brochure. In a new submission to the FDA, Medtronic has presented its InterStim Micro neurostimulator and InterStim SureScan MRI leads into the neuromodulation device market for pre-market approval (PMA). The device is 80% smaller than what is currently in
Register to receive a free U.S. Market Report Suite for Neurological Devices report synopsis and brochure While scientists have a variety of tools on hand to monitor and manipulate living brains, they still lack the ability to observe how large numbers of individual neurons operate in real time. Now, researchers at the Howard Hughes Medical Institute have
Register to receive a free U.S. Market Report Suite for Neurological Devices report synopsis and brochure Stryker recently launched the Surpass Evolve Flow Diverter following approval in March. Surpass Evolve is Stryker’s newest product release into the flow diversion space for the treatment of brain aneurysms. Improving on the already successful existing Surpass platform, this new device
Register to receive a free U.S. Market Report Suite for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices report synopsis and brochure NeuroCatch, Inc. has recently announced the approval of their NeuroCatch™ Platform for a medical device license as Canada’s first objective and rapid neuro-physiological brain function assessment system. The device assesses neurological function through the measurement of event-related
Register to receive a free U.S. Market Report Suite for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices report synopsis and brochure A new approach to brain cancer treatment has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device designation, which denotes that with no approved products with similar capabilities, the FDA will expedite the device’s development in
